Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

20071,074 citationsJournal Articlebronze Open Access

Authors

The combination of bevacizumab and irinotecan is an active regimen for recurrent grade III-IV glioma with acceptable toxicity.

Good health and well-being

Published in: Clinical Cancer Research

Volume 13, Issue 4, pp. 1253-1259

Field-Weighted Citation Impact: 56.70